研究单位：[1]Department of Neurosurgery, China International Neuroscience Institute, Xuanwu Hospital, Capital Medical University,Beijing,Beijing,China,No. 45, Changchun Street[2]Shanghai Fosun Pharmaceutical Industry Development Co., Ltd
A single-center, open-label, non-randomized controlled exploratory study is conducted in the Xuanwu Hospital Capital Medical University to evaluate the efficacy and safety of FCN-159 in patients with brain arteriovenous malformations (BAVM), aiming to overcome the current clinical challenges caused by the lack of available drugs for this disease.
